YHYizhou Joseph He

Yizhou Joseph He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yizhou Joseph He has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer

    by Veronica Rendo, Michael Schubert, Nicholas Khuu, Maria F. Suarez Peredo Rodriguez, Declan Whyte, Xiao Ling, Anouk van Den Brink, Kaimeng Huang, Michelle Swift, Yizhou He, et al.

    While the effect of amplification-induced oncogene expression in cancer is known, the impact of copy-number gains on “bystander” genes is less understood. We create a comprehensive map of dosage compensation in cancer by integrating expression and copy number profiles from over 8000 tumors in The Cancer Genome Atlas and cell lines from the Cancer Cell Line Encyclopedia. Additionally, we analyze 17 cancer open reading frame screens to identify genes toxic to cancer cells when overexpressed. Combining these approaches, we propose a class of ‘Amplification-Related Gain Of Sensitivity’ (ARGOS) genes located in commonly amplified regions, yet expressed at lower levels than expected by their copy number, and toxic when overexpressed. We validate RBM14 as an ARGOS gene in lung and breast cancer cells, and suggest a toxicity mechanism involving altered DNA damage response and STING signaling. We additionally observe increased patient survival in a radiation-treated cancer cohort with RBM14 amplification.


  • Open Access

    A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer

    by Veronica Rendo, Michael Schubert, Nicholas Khuu, Maria F Suarez Peredo Rodriguez, Kaimeng Huang, Michelle Swift, Yizhou He, Johanna Zerbib, Ross Smith, Jonne Raaijmakers, et al.

    Chromosomal gains are among the most frequent somatic genetic alterations occurring in cancer. While the effect of sustained oncogene expression has been characterized, the impact of copy-number gains affecting collaterally-amplified “bystander” genes on cellular fitness remains less understood. To investigate this, we built a comprehensive map of dosage compensations across human cancers by integrating expression and copy number profiles from over 8,000 TCGA tumors and CCLE cell lines. Further, we analyzed the effect of gene overexpression across 17 human cancer ORF screens to provide an overview of genes that prove toxic to cancer cells when overexpressed. Combining these two independent approaches we propose a class of ‘Amplification-Related Gain Of Sensitivity’ (ARGOS) genes. These genes are located in commonly amplified regions of the genome, have lower expression levels than expected by their copy-number status, and are toxic to cancer cells when overexpressed. We experimentally validated CDKN1A and RBM14 as high-confidence pan-cancer ARGOS genes in lung and breast cancer cell line models. We additionally suggest that RBM14’s mechanism of toxicity involves altered DNA damage response and innate immune signaling processes following gene overexpression. Finally, we provide a comprehensive catalog of compensated, toxic, and ARGOS genes as a community resource.


  • Dynamics of the DYNLL1–MRE11 complex regulate DNA end resection and recruitment of Shieldin to DSBs

    by Michelle L. Swift, Rui Zhou, Aleem Syed, Lisa A. Moreau, Bartłomiej Tomasik, John A. Tainer, Panagiotis A. Konstantinopoulos, Alan D. D’andrea, Yizhou Joseph He, Dipanjan Chowdhury

    The extent and efficacy of DNA end resection at DNA double-strand breaks (DSB) determine the repair pathway choice. Here we describe how the 53BP1-associated protein DYNLL1 works in tandem with the Shieldin complex to protect DNA ends. DYNLL1 is recruited to DSBs by 53BP1, where it limits end resection by binding and disrupting the MRE11 dimer. The Shieldin complex is recruited to a fraction of 53BP1-positive DSBs hours after DYNLL1, predominantly in G1 cells. Shieldin localization to DSBs depends on MRE11 activity and is regulated by the interaction of DYNLL1 with MRE11. BRCA1-deficient cells rendered resistant to PARP inhibitors by the loss of Shieldin proteins can be resensitized by the constitutive association of DYNLL1 with MRE11. These results define the temporal and functional dynamics of the 53BP1-centric DNA end resection factors in cells.


  • Open Access

    Dynamics of the DYNLL1/MRE11 complex regulates DNA end resection and recruitment of the Shieldin complex to DSBs

    by Rui Zhou, Michelle L. Swift, Aleem Syed, Kaimeng Huang, Lisa Moreau, John A. Tainer, Panagiotis A. Konstantinopoulos, Alan D. D’andrea, Yizhou Joseph He, Dipanjan Chowdhury

    Extent and efficacy of DNA end resection at DNA double strand break (DSB)s determines the choice of repair pathway. Here we describe how the 53BP1 associated protein DYNLL1 works in tandem with Shieldin and the CST complex to protect DNA ends. DYNLL1 is recruited to DSBs by 53BP1 where it limits end resection by binding and disrupting the MRE11 dimer. The Shieldin complex is recruited to a fraction of 53BP1-positive DSBs hours after DYNLL1 predominantly in the G1 cells. Shieldin localization to DSBs is dependent on MRE11 activity and is regulated by the interaction of DYNLL1 with MRE11. BRCA1-deficient cells rendered resistant to PARP inhibitors by the loss of Shieldin proteins can be re-sensitized by the constitutive association of DYNLL1 with MRE11. These results define the temporal and functional dynamics of the 53BP1-centric DNA end resection factors in cells.

  • SCF FBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis

    by Jin Bai, Kenneth Wu, Meng-Han Cao, Yingying Yang, Yu Pan, Hui Liu, Yizhou He, Yoko Itahana, Lan Huang, Jun-Nian Zheng, et al.

    Significance: Overexpression of human homologue of mouse double minute 2 (HDM2) is associated with aggressive cancer malignancy. It is therefore critical to understand cellular mechanisms for the control of HDM2 abundance. By identifying S kp1- C ullin 1- F BXO22-ROC1 (SCF FBXO22 ) as an E3 ubiquitin ligase for HDM2, our work has significantly improved knowledge of the cellular regulatory network required for the maintenance of HDM2 protein stability. The results of tumor cell invasion, mouse 4T1 breast tumor model study, and human breast cancer tissue expression analyses suggest a role for SCF FBXO22 in the inhibition of breast cancer metastasis by down-regulating HDM2.


  • Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer

    by Kumar Nikhil, Lei Chang, Keith Viccaro, Max Jacobsen, Callista McGuire, Shakti R. Satapathy, Michael Tandiary, Meaghan M. Broman, Gregory Cresswell, Yizhou J. He, et al.


  • DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells

    by Yizhou Joseph He, Khyati Meghani, Marie-Christine Caron, Chunyu Yang, Daryl A. Ronato, Jie Bian, Anchal Sharma, Jessica Moore, Joshi Niraj, Alexandre Detappe, et al.

    Limited DNA end resection is the key to impaired homologous recombination in BRCA1-mutant cancer cells. Here, using a loss-of-function CRISPR screen, we identify DYNLL1 as an inhibitor of DNA end resection. The loss of DYNLL1 enables DNA end resection and restores homologous recombination in BRCA1-mutant cells, thereby inducing resistance to platinum drugs and inhibitors of poly(ADP-ribose) polymerase. Low BRCA1 expression correlates with increased chromosomal aberrations in primary ovarian carcinomas, and the junction sequences of somatic structural variants indicate diminished homologous recombination. Concurrent decreases in DYNLL1 expression in carcinomas with low BRCA1 expression reduced genomic alterations and increased homology at lesions. In cells, DYNLL1 limits nucleolytic degradation of DNA ends by associating with the DNA end-resection machinery (MRN complex, BLM helicase and DNA2 endonuclease). In vitro, DYNLL1 binds directly to MRE11 to limit its end-resection activity. Therefore, we infer that DYNLL1 is an important anti-resection factor that influences genomic stability and responses to DNA-damaging chemotherapy.


  • Call admission control scheme based on maximizing throughput for the multi-beam GEO satellite communication system

    by Jiawei Yu, Gaofeng Cui, Yinlong Ma, Xiuhua Li, Yizhou He

    The increasing multimedia traffic and limited spectrum resource in Geosynchronous (GEO) satellite systems starve for an efficient Call Admission Control (CAC) scheme, which aims to provide acceptable Quality of Service (Qos) to massive users, however, the throughput may not be guaranteed. In order to maximize the total throughput of communication system, a dynamic CAC scheme, named Maximizing Throughput Call Admission Control (MTCAC), is proposed. This scheme ensures the requirements of users' transmission delays while some objective conditions, such as link quality and co-frequency interference, are taken into consideration. The simulation result shows that the performance of communication system could be improved by the scheme proposed.


  • Open Access

    TIRR regulates 53BP1 by masking its histone methyl-lysine binding function

    by Pascal Drané, Marie-Eve Brault, Gaofeng Cui, Khyati Meghani, Shweta Chaubey, Alexandre Detappe, Nishita Parnandi, Yizhou He, Xiao-Feng Zheng, Maria Victoria Botuyan, et al.

    P53-binding protein 1 (53BP1) is a multi-functional double-strand break repair protein that is essential for class switch recombination in B lymphocytes and for sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors. Central to all 53BP1 activities is its recruitment to double-strand breaks via the interaction of the tandem Tudor domain with dimethylated lysine 20 of histone H4 (H4K20me2). Here we identify an uncharacterized protein, Tudor interacting repair regulator (TIRR), that directly binds the tandem Tudor domain and masks its H4K20me2 binding motif. Upon DNA damage, the protein kinase ataxia-telangiectasia mutated (ATM) phosphorylates 53BP1 and recruits RAP1-interacting factor 1 (RIF1) to dissociate the 53BP1–TIRR complex. However, overexpression of TIRR impedes 53BP1 function by blocking its localization to double-strand breaks. Depletion of TIRR destabilizes 53BP1 in the nuclear-soluble fraction and alters the double-strand break-induced protein complex centring 53BP1. These findings identify TIRR as a new factor that influences double-strand break repair using a unique mechanism of masking the histone methyl-lysine binding function of 53BP1.


  • Open Access

    p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway

    by Derek A. Franklin, Yizhou He, Patrick L. Leslie, Andrey P. Tikunov, Nick Fenger, Jeffrey M. Macdonald, Yanping Zhang

    Activation of p53 in response to DNA damage is essential for tumor suppression. Although previous studies have emphasized the importance of p53-dependent cell cycle arrest and apoptosis for tumor suppression, recent studies have suggested that other areas of p53 regulation, such as metabolism and DNA damage repair (DDR), are also essential for p53-dependent tumor suppression. However, the intrinsic connections between p53-mediated DDR and metabolic regulation remain incompletely understood. Here, we present data suggesting that p53 promotes nucleotide biosynthesis in response to DNA damage by repressing the expression of the phosphofructokinase-2 (PFK2) isoform 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a rate-limiting enzyme that promotes glycolysis. PFKFB3 suppression increases the flux of glucose through the pentose phosphate pathway (PPP) to increase nucleotide production, which results in more efficient DNA damage repair and increased cell survival. Interestingly, although p53-mediated suppression of PFKFB3 could increase the two major PPP products, NADPH and nucleotides, only nucleotide production was essential to promote DDR. By identifying the novel p53 target PFKFB3, we report an important mechanistic connection between p53-regulated metabolism and DDR, both of which play crucial roles in tumor suppression.